Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640250 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
A Phase 2 study, sponsored by Allerderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00640250: Completed Phase 2 study, sponsored by Allerderm.
NCT00640250 is a Phase 2 study that has completed, run by Allerderm. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640250, a Phase 2 study, has completed, sponsored by Allerderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").
Primary Outcome
Lowest concentration eliciting 1+ or 2+ positive reactions in 70-90% of subjects
Interventions
- BIOLOGICAL T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00640250 record still lists
NCT00640250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens is the first listed.
NCT00640250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00640250 about?
NCT00640250 is a clinical study titled "Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response". We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact de...
What is the current status of trial NCT00640250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00640250?
The interventions under investigation include: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00640250?
This trial is sponsored by Allerderm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00640250's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia